

SVHCD QUALITY COMMITTEE

AGENDA WEDNESDAY, AUGUST 23, 2023

5:00 p.m. Regular Session

TO BE HELD VIA ZOOM VIDEOCONFERENCE

To Participate Via Zoom Videoconferencing use the link below:

 $\frac{https://sonomavalleyhospital-}{org.zoom.us/j/91601200156?pwd=cXYzdUs2MEZnS2xHVUJyL}\\ 3phWWdGQT09.$

and Enter the **Meeting ID: 916 0120 0156**

Passcode: 891667

To Participate via Telephone only, dial: 1-669-900-9128 or 1-669-219-2599

AGENDA ITEM	RECOMM	ENDATION
In compliance with the Americans with Disabilities Act, if you require special accommodations to attend a District meeting, please contact the District Clerk, Monique Crayton, at mcrayton@sonomavalleyhospital.org or 707.935.5005 at least 48 hours prior to the meeting.		
MISSION STATEMENT The mission of the SVHCD is to maintain, improve, and restore the health of everyone in our community.		
1. CALL TO ORDER/ANNOUNCEMENTS	Kornblatt Idell	
2. PUBLIC COMMENT SECTION At this time, members of the public may comment on any item not appearing on the agenda. It is recommended that you keep your comments to three minutes or less. Under State Law, matters presented under this item cannot be discussed or acted upon by the Committee at this time. For items appearing on the agenda, the public will be invited to make comments at the time the item comes up for Committee consideration.	Kornblatt Idell	
3. CONSENT CALENDAR • Minutes 07.26.23	Kornblatt Idell	Action
4. PHARMACY QA/PI	Kutza	Inform
5. QUALITY INDICATOR PERFORMANCE AND PLAN	Cooper	Inform
6. POLICIES AND PROCEDURES	Cooper	Inform
7. CLOSED SESSION: a. Calif. Health & Safety Code §32155: Medical Staff Credentialing & Peer Review Report	Kornblatt Idell	Action
8. ADJOURN	Kornblatt Idell	



SONOMA VALLEY HEALTH CARE DISTRICT QUALITY COMMITTEE

July 26, 2023, 5:00 PM

MINUTES

Via Zoom Teleconference

Members Present – Via	Members Present cont.	Excused	Public/Staff – Via Zoom
Zoom			
Susan Kornblatt Idell		Carol Snyder	Jessica Winkler, DNP, RN, NEA-BC,
Carl Speizer, MD		Kathy Beebe, RN PhD	CCRN-K, CNO
Michael Mainardi, MD		Judith Bjorndal, MD	Kylie Cooper, RN, BSN, CPHQ,
Ingrid Sheets, EdD, MS, RN		Howard Eisenstark, MD	MBA, Quality and Risk Mgmt.
			John Hennelly, CEO
			Paul Amara, MD
			Dawn Kuwahara, RN, BSN
			Nicolas Hadjiyianni, Lab Manager
			Louie Lacson, CLS

AGENDA ITEM	DISCUSSION	ACTION
1. CALL TO ORDER/ANNOUNCEMENTS	Kornblatt Idell	
	Meeting called to order at 5:07 p.m.	
2. PUBLIC COMMENT	Kornblatt Idell	
	None	
3. CONSENT CALENDAR	Kornblatt Idell	ACTION

• QC Minutes 06.28.23	Minutes of the 06.28.23 meeting were approved as presented.	MOTION: by Mainardi to approve, 2 nd by Speizer All in favor.
4. LAB QA/PI	Kuwahara, Hadjiyianni, Lacson	INFORM
	Ms. Kuwahara presented the LAB QA/PI presentation. Overview given of laboratory staff and Scope of Services. Based on a question from Ms. Sheets Ms. Kuwahara explained that Quest is currently the reference lab used by SVH for those tests that cannot be performed in house. Patients can bring their quest order to SVH to have labs performed. Those with Partnership insurance must go to Quest for their lab draws. Accomplishments regarding the EPIC Beaker project were discussed. This was a great accomplishment for the lab and required 2 full-time staff members to be engaged in the implementation of this project. Challenges that were discussed were staffing and aging equipment. The lifespan on lab equipment is 7 years and some equipment will need to be replaced this fiscal year. Some of the equipment to be replaced will be the hematology analyzers. There is a current recruitment for a Lab Supervisor underway. Ms. Kuwahara reported that due to a significant decrease in COVID testing the forecasted volumes for 2023 have decreased. Dr. Mainardi asked when the UCSF interface will be completed. It was anticipated this July, but this has been pushed out to September. The LAB QAPI was presented. Critical value reporting fell below the target. The fallout was explained by Mr. Hadjiyianni. It was due to critical tests not being documented correctly by the CLS regarding a critical test that was called to the provider. Direct education was done on this. MRSA now has a 2-hour turnaround time as opposed to 36 hours as we are now performing the test via PCR.	
5. QUALITY INDICATOR PERFORMANCE PLAN	Cooper	INFORM

	Ms. Cooper shared the quality indicator performance for the month of June 2023. RN blood culture contamination was above the target. There is a specific action plan in place with ED staff regarding this measure. Code stroke called time was above the target, this was attributed to 1 patient that had an atypical presentation and therefore code stroke time called was delayed. ED throughput time significantly improved despite record volumes. Lower acuity could have contributed. Sepsis core measure did not meet the target, fall out attributed to MD not using the Sepsis Order Set in EPIC. Hand Hygiene improvements seen in June. Monthly and Quarterly CIHQ corrective action plans for conditional and standing findings was presented. Improvements seen in Continuous Observation of At Risk Patients, still not meeting goal, education has been provided to ED MD's regarding ordering of close observation. Fall outs in other monitoring plans presented and action plans discussed. Rate my Hospital Scores for June presented.	
6. POLICIES AND PROCEDURES	Cooper	INFORM
	Summaries of changes were reviewed for the following policies: Administration of Medications Advanced Directives Contrast Reactions 7630-125 Infection Prevention Program Infection Prevention Risk Assessment Management of Radiographic Contrast Media MRI Code Blue Procedure MRSA Active Surveillance Culture (ASC) Venipuncture by Technologists 7630-237 RETIRE Cardiac Exercise Testing Precautions, Indication and Complications Cardiac Stress Testing Addendum Cardiolite Testing	

8.	CLOSED SESSION/REPORT ON CLOSED SESSION	accordingly. Kornblatt Idell	ACTION
7.	MEETING DATES FOR THE BALANCE OF 2023	Dobutamine Stress Testing ECG Interpretation Kornblatt Idell Ms. Kornblatt Idell proposed combining the September/October and November/December Quality Committee Meetings. The September/October meeting will take place on Wednesday, October 25 th . The November/December meeting date will be determined. The Committee agreed to the proposed changes. Staff will revise meeting invites, and email updates	INFORM
		Echocardiogram Procedure Echocardiography with Contrast Fire Safety-Imaging Dept Fire Safety-MRI Myocardial Perfusion Testing Lexiscan Treadmill Test Pediatric Electrocardiogram Performing Complete Transthoracic Echocardiograms, protocol for	

Epic-update Adverse Drug Events Antimicrobial Stewardship Controlled Substances **Pyxis Utilization** IV Room **Pharmacy Services**



Epic

- 8 months in
- Staff comfortable with how to use
- Moving on to mining the large amount of data available for QA
 - Outpatient infusion reimbursement
 - Opioid utilization
 - Antimicrobial stewardship





Adverse Drug Events

- Administration Errors Per 10,000 Doses
- High Risk Med Errors Per 10,000 Doses
- Near Miss %
- Smart Pump- No Drug Selected
- Smart Pump- Hard Alerts
- Smart Pump- Soft Alerts




Rx-ADEs-High Risk Med Errors Per 10,000 Doses (M)









Rx-Smart Pump- No Drug Selected











Rx-Smart Pump- Soft Alerts







Antimicrobial Stewardship


- Cefepime DOT
- Ertapenem DOT
- Levofloxacin DOT
- Meropenem DOT
- Pip-Tazo DOT
- Antimicrobial Spend PAPD (\$)




Rx-Antimicrobial Spend PAPD (M)



8.82 Bet. Target & Alarm 💠 Improved



₹ 6.51 m/a ♣10.00 • 8.00





Controlled Substances

- Controlled Substance Audit-Anesthesia
- Controlled Substance Audit-Inpatient
- C2 Safe Reconciliation
- Nursing Unit Pyxis Reconciliation



Rx-Controlled Substance Audit-Anesthesia

Belladonna and Opium 60mg supp

Dextroamphet-Amphet 10mg tab

Cocaine 4% soln

Fentanyl 100mcg patch

Fentanyl 12mcg patch

Fentanyl 25mcg patch

Fentanyl 1000mcg/20ml vial

0

94

4

42

0

0

0

14

0


0

0

0

0

0



0

0

0

6/1/2023

0

94

28

94

28

0.00%

0.00%

0.00%

0.00%

0.00%



IV Room

- Cleanroom Certification
- Cleanroom Contact Plates
- Cleanroom End Product Testing
- Cleanroom Glovetip Testing
- Cleanroom Hood Cleaning
- Cleanroom Quantitative Analysis
- Cleanroom Room Cleaning-Daily
- Cleanroom Room Cleaning-Weekly
- Cleanroom Written Competencies




USP 797


- Changes in how we use different hoods
- Changes in training requirements
- Changes in competency requirements



Pharmacy Services

- After Hours Interventions
- After Hours Pharmacy ED TAT
- After Hours Pharmacy Errors
- Clinical Interventions-Dollars Saved








Pyxis

- ER Pyxis Overrides
- Pyxis Overrides
- Pyxis Stockouts

Rx-ER Pyxis Overrides





Aug 16, 2023 14:32:18

Quality Indicator Performance & Plan

August Board Quality

Data for July 2023



Mortality

Performance Most Recent

Met

0/1

Indicator

History

0

Period

								IIII	^
Acute Car	are Mortality Rate (M)								
	100%	Target	2 20/	Deteriorated		45.00/			2.724
History		Met	2.2% 1/46	▲ Deteriorated	Jul 2023	15.3%	n/a	n/a	2.7%
COPD M	fortality Rate M								
	100%	Target	t 0.0%	- No Change	T-1-2022	0.50/		(-	0.09/
History		Met	0/2	- No Change	Jul 2023	8.5%	n/a	n/a	0.0%
Congestiv	ve Heart Failure Mortality Rate M								
	91% 9%	Target	t 0.0%	- No Change	T 1 2022	11.50/	,	,	0.00/
History		Met	0.0%	- No Change	Jul 2023	11.5%	n/a	n/a	0.0%
Pneumoni	nia Mortality Rate M								
	8396 1796	Target	t 0.0%	- No Change	* 1 2022	45.20/	-/-		4.59/
History		Met	0.0%	- No Change	Jul 2023	15.6%	n/a	n/a	4.5%
Ischemic	Stroke Mortality Rate M								
	100%	Target	t 0.0%	- No Change	7 1 2022	40.00/	./-		0.09/
History		Met	0.0%	- No Change	Jul 2023	13.8%	n/a	n/a	0.0%
Hemorrh	nagic Stroke - Mortality Rate (M)								
	8396 1796	Target	t 0.0%	No Changa	- 2022	2.207	4.007	,	46.70/
History		Met	0.0%	- No Change	Jun 2023	0.0%	1.0%	n/a	16.7%
Indicator		Performance	Most Recent	Trend	Period	Θ	.	lidi.	₹
Sepsis, Se	evere - Mortality Rate (M)								Ī
	9196 996	Target	0.0%	— No Change	Jul 2023	25.0%	n/a	n/a	2.6%
History		Met	0/2		Jui 2022		AD 14	AF 14.	2.55
Septic Sho	nock - Mortality Rate (M)								
	7596 2596	Target	0.0%	— No Change	Jul 2023	25.0%	n/a	n/a	14.8%
History		Met	0.0		Jul 2023	25.070	11 4	n a	14.070

AHRQ Patient Safety Indicators

Indicator		Performance	Most Recent	Trend	Period	⊚	A	lidii	₹
PSI 90 (v2	021) Midas Patient Safety Indicators Composite, ACA (M)								
	100%	Target	0.00	NI- Ch					
History		Met	0.00 0/0.007	- No Change	Jul 2023	0.00	n/a	n/a	0.00
PSI 90 (v2	021) Patient Safety Indicators Composite, ACA - Volume (M)								
	100%	Target		— No Chango			,	,	
History		Met	0	- No Change	Jul 2023	0	n/a	n/a	0

The Patient Safety Indicators 90 (PSIs)

- o PSI 03 Pressure Ulcer
- PSI 06 latrogenic Pneumothorax Rate
- PSI 08 In Hospital Fall with Hip Fracture
- PSI 09 Perioperative Hemorrhage or Hematoma
- PSI 10 Postoperative Acute Kidney Injury Requiring Dialysis
- PSI 11 Postoperative Respiratory Failure
- PSI 12 Perioperative Pulmonary Embolism or DVT
- PSI 13 Postoperative Sepsis
- o PSI 14a Postoperative Wound Dehiscence, Open
- o PSI 14b Postoperative Wound Dehiscence, Non-Open
- PSI 15 Accidental Puncture or Laceration




Adverse Events Reporting

Zero Adverse events including Pre-Op/Post Op discrepancies, adverse events from Anesthesia or operative adverse events

Indicator		Performance	Most Recent	Trend	Period	⊚		āli	×
Adverse E	Event SE (M) volume								
	100%	Target		37 69					
History		Met	0	- No Change	Jul 2023	0	1	n/a	0



Blood Products





Significant Medication Errors and Adverse Drug Reactions

No Adverse Drug Reactions

Indicator	Performance	Most Recent	Trend	Period	•	٨	lidi	×
Rx-ADEs-High Risk Med Errors Per 10,000 Doses (M)								
100%	Target	0.00	¬ I		4.40	2.00	,	0.00
History History	Met	0.00 0/66281	❖ Improved	Jul 2023	1.13	2.00	n/a	0.09
Rx-Administration Errors Per 10,000 Doses Dispensed								
100%	Target	0.15	- Improved	T-1 2022	1.00	2.00	(-	0.20
History	Met	1/66281	❖ Improved	Jul 2023	1.00	3.00	n/a	0.30



Patient Falls Preventable Harm


Indicator			Performance	Most Recent	Trend	Period	•	.	ūli	×
RM ACU	TE FALL- All (M) per 1000 patient days									
	8396	896 996	Target	0.00	- No Change		0.75	4.00	,	
History			Met	0/183	- No Change	Jul 2023	3.75	4.00	n/a	1.61
RM ACU	TE FALL- WITH INJURY (M) per 1000 patient d	ays								
	100%		Target	0.00	— No Change					
History			Met	0.00	- No Change	Jul 2023	3.75	4.00	n/a	0.00



Readmissions

Indicator	Performance	Most Recent	Trend	Period	Θ	A	lidi	×
30-DV Inpatients - % Readmit to Acute Care within 30 Days (M)								
100%	Target							
History History	Met	4.55% 2/44	Improved	Jul 2023	15.30%	15.50%	n/a	5.44%
COPD, CMS Readm - % Readmit within 30 Days, ACA (M)								
8396 1796	Target	0.0%	- No Change	T-1 2022	10.59/	20.09/		0.48/
History History	Met	0/1	— No Change	Jul 2023	19.5%	20.0%	n/a	9.4%
HF, CMS Readm Rdctn - % Readmit within 30 Days, ACA (M)								
9196 996	Target	0.0%	- No Change	T 1 2022	24.69/	22.00/	,	0.00/
History Market M	Met	0/1	— No Change	Jul 2023	21.6%	22.0%	n/a	0.0%
Hip/Knee, CMS Readm Rdctn - % Readmit within 30 Days, ACA (M)								
5896 996 3396	Target	0.09/	N. Characa					
History	Met	0.0% 0/1	- No Change	Jul 2023	4.0%	5.0%	n/a	6.7%
PNA, CMS Readm Rdctn - % Readmit within 30 Days, ACA (M)								
9196	Target	0.0%	- No Change		4.5.507	47.007		5.007
History History	Met	0/1	— No Change	Jul 2023	16.6%	17.0%	n/a	5.0%
Sepsis, Severe - % Readmit within 30 Days (M)								
100%	Target	0.0%	- No Change					
History History	Met	0.0%	- No Change	Jul 2023	12.0%	13.0%	n/a	0.0%
Septic Shock - % Readmit within 30 Days (M)								
100%	Target	0.0%	- No Change	T 1 2022	12.29/	14.00/	,	0.287
History	Met	0.0%	No Change	Jul 2023	13.3%	14.0%	n/a	0.2%
							WALLEY HO	CDITAI

Blood Culture Contamination



Month	RN-Contaminated Culture Reports (num)	Blood Cultures Drawn by RN (den)	Percent
Jul 2023	2	89	2.2%
Jun 2023	3	98	3.1%
May 2023	1	111	0.9%
Apr 2023	7	104	6.7%
Mar 2023	6	103	5.8%
Feb 2023	2	95	2.1%
Jan 2023	4	88	4.5%
Dec 2022	4	109	3.7%
Nov 2022	3	124	2.4%
Oct 2022	2	74	2.7%
Sep 2022	0	78	0.0%
Aug 2022	2	88	2.3%



CIHQ Stroke Certification Measures

Performance Most Recent

Undefined

Indicator

CDSTK-12|Median-Door to tPA |M| minutes

History

75%

Indicator	Performance	Most Kecent	1 rena	Period	•	÷	lıllı	×
CDSTK-03 Median- Code Stroke Called M elapsed time (mins)								
91%	Target	2	▼ Improved	Jul 2023	10	11	n√a	2
History	Met		V	Jui 2023	10		IV d	
CDSTK-04 Median- Door to Phys Eval M minutes								
100%	Target	1.50	❖ Improved	Jul 2023	10.00	11.00	n√a	1.50
History History	Met		•	Jul 2023	10.00	11.50	IF 0.	1.50
CDSTK-05 Median-Door to CT Scanner M elapsed time (minutes)								
100%	Target	5.50	❖ Improved	Jul 2023	25.00	26.00	n√a	7.50
History History	Met		•	V 62 2 2 2 2 3	25.00	20.00	AN 14	7.20
CDSTK-06 Median- Neuro Consult Contacted M minutes								
100%	Target	16.50	Improved	Jul 2023	30.00	31.00	n√a	16.00
History History	Met		-	V 2-2-2				
CDSTK-07 Median- CT Read by Radiology M minutes								1
100%	Target	22.50	Improved	Jul 2023	45.00	46.00	n√a	28.75
History History	Met		-	VIII 2-2-2				
CDSTK-08 Median- Lab Results Posted M minutes								
100%	Target	17.00	❖ Improved	Jul 2023	45.00	46.00	n√a	23.00
History History	Met		· ·	Jul 2023	73.00	70.00		25.00
CDSTK-10 Median- Door to EKG Complete M minutes								
100%	Target	32.00	Improved	Jul 2023	60.00	61.00	n√a	35.25
History History	Met	32.00	V	Jui 2023	00.00	01.00	ID &	
CDSTK-11 Median-Door to tPA Decision M minutes								
83% 17%	Target	33.50	❖ Improved	Jul 2023	60.00	61.00	n/a	41.00
History	Met		•					


Jul 2023

60.00

61.00

36.00

Utilization Management



Geometric mean is a statistical/mathematical term that is applied in many other areas outside of health care. This is calculated by multiplying all of the lengths of stay and then taking the nth root of that number (where n=number of patients). (Minimizes the impact of outliers)

The Case Mix Index (CMI) is the average relative DRG weight of a hospital's inpatient discharges, calculated by summing the Medicare Severity-Diagnosis Related Group (MS-DRG) weight for each discharge and dividing the total by the number of discharges.



Core Measures

Performance	Most Recent	Trend	Period	Θ	A	idi	×
							7
Target							,
Met	100.0% 9/9	- No Change	Jul 2023	88.0%	50.0%	n/a	100.0%
Performance	Most Recent	Trend	Period	•	.	lidi	×
Target							
Met	130.00	♠ Deteriorated	Jul 2023	132.00	140.00	n/a	148.25
Performance	Most Recen	t Trend	Period	•		ūli	₹
Target	,						
Met	0.6% 5/825	Deteriorated	Jul 2023	2.0%	2.5%	n/a	1.1%
Performance	Most Recent	Trend	Period	•	4	liú	₹
Target	75.0%						66.7%
	Target Met Performance Target Met Performance Target Met Performance	Target 100.0% Met 9/9 Performance Most Recent Target 130.00 Performance Most Recent Target 0.6% Met 5/825 Performance Most Recent	Target Most Recent Trend Target Most Recent Trend Target Met 130.00 Deteriorated Performance Most Recent Trend Target Most Recent Trend Target Met 5/825 Performance Most Recent Trend	Target Most Recent Trend Period Target Most Recent Trend Period	Target 100.0%	Target Met 100.0% 9/9 No Change Jul 2023 88.0% 50.0% Performance Most Recent Trend Period ● ♠ Target Met 130.00 Deteriorated Jul 2023 132.00 140.00 Performance Most Recent Trend Period ● ♠ Target Met 5/825 Deteriorated Jul 2023 2.0% 2.5% Performance Most Recent Trend Period ● ♠	Target 100.0%



Core Measures Sepsis

Indicator		Performance	Most Recent	Trend	Period	•	.	láti	₹
SEP-1 Ea	rly Management Bundle, Severe Sepsis/Septic Shock (M)								
	33% 67%	Breaches	75.0%		Jul 2023	81.0%	80.0%	n/a	57.7%
History		Alarm	3/4						211112
SEPa - Se	SEPa - Severe Sepsis 3 Hour Bundle (M)								
	3396 S96 5996	Target	100.0%	♠ Improved		0.1.007	00.007	,	00.007
History		Met	4/4	A Improved	Jul 2023	94.0%	90.0%	n/a	82.3%
SEPb - Se	SEPb - Severe Sepsis 6 Hour Bundle (M)								
	58% 42%	Target	100.09/						
History		Met	100.0% 4/4	♠ Improved	Jul 2023	100.0%	90.0%	n/a	88.2%




Infection Prevention

Indicator		Performance	Most Recent	Trend	Period	Θ	.	lálí	×
IC-Survei	illance HAI-C.DIFF Inpatient infections per 10k pt days M								
	9296 896	Target	•	— No Change	7 1 2022			,	
History		Met	0	- No Change	Jul 2023	1	1	n/a	0
IC-Survei	illance HAI-CAUTI Inpatient infections per 10k patient days M								
	92% 8%	Target	0	— No Change	Jul 2023	1	1	w.fe	0
History		Met	U	- No Change	JUI 2023	1	1	n/a	Ů
IC-Survei	illance HAI-CLABSI Inpatient infections per 10k patient days M								
	96% 4%	Target	0	- No Change	T 1 2022			' -	0
History		Met	0	- No Change	Jul 2023	1	1	n/a	0
IC-Survei	illance HAI-MRSA Inpatient infections per 10k patient days M								
	100%	Target	0	- No Change	T 1 2022			<i>'-</i>	0
History		Met	0	- No Change	Jul 2023	1	1	n/a	0
IC-Survei	illance HAI-SSI infections per 10k pt days M								
	100%	Target	0	- No Change				,	•
History		Met	U	- No Change	Jul 2023	1	1	n/a	0
QA-02 Ha	and Hygiene Practices Monitored M								
896	1796 7596	Breaches	0.40/	- Determinanted					
History		Alarm	84% 132/158	Deteriorated	Jul 2023	90%	85%	n/a	79%



CIHQ Corrective Action Plan Monthly Compliance Condition Level Findings





Patient Satisfaction

HCAHPS reported Quarterly





Monthly report (copy) INPATIENT

Generated: 8/17/2023 11:38 AM ET

Service Date Range: 4/1/2023 - 6/30/2023

Sonoma Valley Hospital - System (15704)

Inpatient

Questions	Top Box	n	STATE CA Score	All PG Database Score
*Rate hospital 0-10	64.91	57	72.01	70.24
*Recommend the hospital	74.55	55	72.89	69.31
*Comm w/ Nurses Domain Performance	81.29	57	(77.60)	(78.93)
*Nurses treat with courtesy/respect	94.74	57	83.79	85.64
*Nurses listen carefully to you	73.68	57	75.18	76.44
*Nurses expl in way you understand	75.44	57	73.84	74.75
*Response of Hosp Staff Domain Performance	68.15	50	62.67	(63.61)
*Call button help soon as wanted it	73.33	45	61.40	62.15
*Help toileting soon as you wanted	62.96	27	64.08	64.43
*Comm w/ Doctors Domain Performance	86.71	56	(78.50)	(79.27)
*Doctors treat with courtesy/respect	92.86	56	83.83	85.46
*Doctors listen carefully to you	83.33	54	77.07	77.78
*Doctors expl in way you understand	83.93	56	74.61	74.57
*Hospital Environment Domain Performance	59.59	57	62.62	65.81
*Cleanliness of hospital environment	74.55	55	72.94	72.13
*Quietness of hospital environment	44.64	56	52.29	59.44



Monthly report (copy) INPATIENT

Generated: 8/17/2023 11:38 AM ET

Service Date Range: 4/1/2023 - 6/30/2023 Sonoma Valley Hospital - System (15704)

Inpatient

Questions	Top Box	n	STATE CA Score	All PG Database Score
*Comm About Medicines Domain Performance	(56.99)	34	(61.80)	(60.27)
*Tell you what new medicine was for	76.47	34	74.53	73.93
*Staff describe medicine side effect	37.50	32	49.07	46.59
*Discharge Information Domain Performance	87.39	52	87.26	86.37
*Staff talk about help when you left	86.54	52	85.60	84.59
*Info re symptoms/prob to look for	88.24	51	88.92	88.17
*Care Transitions Domain Performance	38.37	57	53.01	(52.15)
*Hosp staff took pref into account	33.33	57	47.15	46.43
*Good understanding managing health	38.60	57	52.38	51.37
*Understood purpose of taking meds	43.18	44	59.48	58.62





Monthly report (copy) OAS

Generated: 8/17/2023 11:36 AM ET

Service Date Range: 4/1/2023 - 6/30/2023 Sonoma Valley Hospital - System (15704)

Healing Here at Home

Ambulatory Surgery

Questions	Top Box	n	All PG Database Score	State of California Score
*Facility rating 0-10	87.30	126	87.99	85.79
*Recommend the facility	85.60	125	85.44	83.79
*Communication Domain Performance	93.07	128	92.18	90.21
*Provided needed info re procedure	94.44	126	92.52	90.86
*Instructions good re preparation	96.67	120	94.37	92.96
*Procedure info easy to understand	96.83	126	93.81	92.18
*Anesthesia info easy to understand	96.52	115	94.37	92.47
*Anes side effect easy to understand	80.87	115	85.87	82.54
*Facility/Personal Trtment Domain Performance	96.04	128	97.04	96.08
*Check-in run smoothly	92.06	126	95.44	94.07
*Facility clean	97.64	127	97.99	97.25
*Clerks and receptionists helpful	93.65	126	96.19	94.92
*Clerks and reception courteous	97.66	128	97.52	96.64
*Staff treat w/ courtesy, respect	98.44	128	98.10	97.48
*Staff ensure you were comfortable	96.80	125	96.99	96.10



Monthly report (copy) OAS

Generated: 8/17/2023 11:36 AM ET

Service Date Range: 4/1/2023 - 6/30/2023 Sonoma Valley Hospital - System (15704)

Ambulatory Surgery

uestions	Тор Вох	n	All PG Database Score	State of California Scor
*Discharge Domain Performance	97.71)	126	96.79	95.88
*Written discharge instructions	98.35	121	97.68	97.10
*Instructions regarding recovery	87.90	124	87.65	84.55
*Information re subsequent pain	100.00	107	98.43	97.91
*Information re subsequent nausea	100.00	95	98.45	97.84
*Information re subsequent bleeding	100.00	96	98.98	98.42
*Info on response to infection	100.00	94	99.55	99.41
Nurses Overall	91.18	125	89.36	87.45
Nurses concern for comfort	91.87	123	89.85	87.87
Info nurses gave to prep for proc	89.34	122	88.83	86.84
Nurses response concerns/questions	92.37	118	89.43	87.66
Care Provider Overall	80.30	123	84.22	(80.17)
CP explanation about proc	81.82	121	84.94	81.05
Info CP shared re how proc went	75.42	118	83.00	77.99
CP response to concerns/questions	82.76	116	86.84	83.40
CP expln why proc important	81.25	112	82.06	78.14
Staff worked together care for you	91.06	123	90.37	88.51

Rate My Hospital Scale 1-5 July Data





Rate My Hospital Scale 1-5

Sonoma Valley Hospital / Medical Imaging

169

4.783 95% CI: 4.737—4.829



Sonoma Valley Hospital / Hand and Physical Therapy

120

4.949 95% CI: 4.932—4.966





Rate My Hospital Scale 1-5

Sonoma Valley Hospital / Outpatient Surgery

136







Document Tasks By Committee

Listing of currently pending and/or upcoming document tasks grouped by committee.

Sonoma Valley Hospital

Run by: Newman, Cindi (cnewman) Run date: 08/17/2023 7:32 PM

Report Parameters

Filtered by: Document Set: - All Available Document Sets -

Committee: 07 BOD-Quality (P&P Review)

Include Current Tasks: Yes Include Upcoming Tasks: No

Grouped by: Committee

Sorted by: Document Title

Report Statistics

Committee:

Total Documents: 20

07 BOD-Quality (P&P Review)

Committee Members: Crayton, Monique (mcrayton), Finn, Stacey (sfinn), Newman, Cindi (cnewman)

Current Approval Tasks (due now)

 Document
 Task/Status
 Pending Since
 Days Pending

 Access to Patient Information for Medication Management
 Pending Approval
 8/17/2023
 0

Medication Management Policies (MM)

Summary Of Changes: Reviewed, no changes

Moderators: Newman, Cindi (cnewman)
Lead Authors: Kutza, Chris (ckutza)

Approvers: 01 P&P Committee -> 04 MS-Performance Improvement/Pharmacy & Therapeutics Committee - (Committee) -> 05 MS-

Medical Executive - (Committee) -> 07 BOD-Quality (P&P Review) - (Committee) -> 09 BOD-Board of Directors - (Committee)

Adverse Drug Events-Quality Assurance Pending Approval 8/17/2023 0

Medication Management Policies (MM)

Summary Of Changes: Minor formatting changes; updated date accessed for references; deleted obsolete reference link.

Moderators: Newman, Cindi (cnewman)
Lead Authors: Kutza, Chris (ckutza)
ExpertReviewers: Cooper, Kylie (kcooper)

Approvers: 01 P&P Committee -> 04 MS-Performance Improvement/Pharmacy & Therapeutics Committee - (Committee) -> 05 MS-

Medical Executive - (Committee) -> 07 BOD-Quality (P&P Review) - (Committee) -> 09 BOD-Board of Directors - (Committee)

 Approved Panel List 7500-04
 Pending Approval
 8/17/2023
 0

Clinical Lab Dept

Summary Of Changes: Edited current panels offered

Added Definition of STAT, ROUTINE and BATCH

Added table of laboratory tests

This is being replaced to include TATs.

Moderators: Newman, Cindi (cnewman)
Lead Authors: Ramos, Karen (kramos)

Approvers: Kuwahara, Dawn (dkuwahara) -> 01 P&P Committee - (Committee) -> 02 MS-Medicine Department - (Committee) -> 03 MS-

Surgery Department - (Committee) -> 04 MS-Performance Improvement/Pharmacy & Therapeutics Committee -

(Committee) -> 05 MS-Medical Executive - (Committee) -> 07 BOD-Quality (P&P Review) - (Committee) -> 09 BOD-Board of

Directors - (Committee)

Page 1 of 5 HospitalPORTAL

Run by: Newman, Cindi (cnewman) Run date: 08/17/2023 7:32 PM

0

Listing of currently pending and/or upcoming document tasks grouped by committee.

Clozapine REMS Procedure 8390-08 Pending Approval 8/17/2023

Pharmacy Dept

Summary Of Changes: Simplified instructions for registering on the REMS website to simply indicate following instructions on the website since

they change on occasion

Simplified step by step for accessing and confirming patient eligibility by referring to website as above.

Updated REMS phone number

Removed embedded attachments and added separate document attachment

Moderators: Newman, Cindi (cnewman)
Lead Authors: Kutza, Chris (ckutza)

Approvers: 01 P&P Committee -> 04 MS-Performance Improvement/Pharmacy & Therapeutics Committee - (Committee) -> 05 MS-

Medical Executive - (Committee) -> 07 BOD-Quality (P&P Review) - (Committee) -> 09 BOD-Board of Directors - (Committee)

Controlled Substance Distribution for AnesthesiaPending Approval8/17/20230

Medication Management Policies (MM)

Summary Of Changes: Updated language to remove obsolete portions of the process referring to the paper anesthesia record that are now

electronic in Epic.

Moderators: Newman, Cindi (cnewman)
Lead Authors: Kutza, Chris (ckutza)

Approvers: 01 P&P Committee -> 04 MS-Performance Improvement/Pharmacy & Therapeutics Committee - (Committee) -> 05 MS-

Medical Executive - (Committee) -> 07 BOD-Quality (P&P Review) - (Committee) -> 09 BOD-Board of Directors - (Committee)

Fentanyl PatchPending Approval8/17/20230

Medication Management Policies (MM)

Summary Of Changes: Updated section on removal and disposal to reflect current practice using Epic

Moderators: Newman, Cindi (cnewman)
Lead Authors: Kutza, Chris (ckutza)

Approvers: 01 P&P Committee -> 04 MS-Performance Improvement/Pharmacy & Therapeutics Committee - (Committee) -> 05 MS-

Medical Executive - (Committee) -> 07 BOD-Quality (P&P Review) - (Committee) -> 09 BOD-Board of Directors - (Committee)

Floorstock Medications Pending Approval 8/17/2023 0

Medication Management Policies (MM)

Summary Of Changes: Clarified areas that are exempt from Profile Override process to include only OR and Medical Imaging to match current

practice

Moderators: Newman, Cindi (cnewman)
Lead Authors: Kutza, Chris (ckutza)

Approvers: 01 P&P Committee -> 04 MS-Performance Improvement/Pharmacy & Therapeutics Committee - (Committee) -> 05 MS-

Medical Executive - (Committee) -> 07 BOD-Quality (P&P Review) - (Committee) -> 09 BOD-Board of Directors - (Committee)

Herbal and Natural Product Use Pending Approval 8/17/2023 0

Medication Management Policies (MM)

Summary Of Changes: Reviewed, no changes. Need to update reviewer section to match current formatting standards

Moderators: Newman, Cindi (cnewman)
Lead Authors: Kutza, Chris (ckutza)

Approvers: 01 P&P Committee -> 04 MS-Performance Improvement/Pharmacy & Therapeutics Committee - (Committee) -> 05 MS-

Medical Executive - (Committee) -> 07 BOD-Quality (P&P Review) - (Committee) -> 09 BOD-Board of Directors - (Committee)

 High Alert Medications
 Pending Approval
 8/17/2023
 0

 Medication Management Policies (MM)

Page 2 of 5 HospitalPORTAL

Run by: Newman, Cindi (cnewman) Run date: 08/17/2023 7:32 PM

Listing of currently pending and/or upcoming document tasks grouped by committee.

Summary Of Changes: Reviewed, no changes

Moderators: Newman, Cindi (cnewman)
Lead Authors: Kutza, Chris (ckutza)

Approvers: 01 P&P Committee -> 04 MS-Performance Improvement/Pharmacy & Therapeutics Committee - (Committee) -> 05 MS-

Medical Executive - (Committee) -> 07 BOD-Quality (P&P Review) - (Committee) -> 09 BOD-Board of Directors - (Committee)

Intravenous Contrast Admin Pending Approval 8/17/2023 0

Diagnostic Services Dept Policies

Summary Of Changes: Updated policy to include protocol language to meet CIHQ standards.

" Administration of contrast and medications inherent to the examination will be in accordance with the procedures defined in this policy and following protocols used for contrast/medication administration that are based on the type of examination ordered and define the type, dose and route of contrast."

"

- The radiologist or LIP reviews the order for radiology procedures with IV contrast to determine and/or modify the
 appropriate protocol based on the clinical indications for the procedure and patient status. The assigned protocol is entered
 or indicated in the radiology information system (RIS) or electronic medical record (EMR).
- For those procedures where a contrast protocol has been established and approved by the Pharmacy and Therapeutics Committee the technologist may administer the contrast, following the established protocol, using a protocol order."

Added P&T Committee to list of approvers.

Moderators: Newman, Cindi (cnewman)

Lead Authors: Kutza, Chris (ckutza), Young, Dave (dyoung)

ExpertReviewers: Kutza, Chris (ckutza), Medical Director-Diagnostic Radiology

Approvers: Kuwahara, Dawn (dkuwahara) -> 01 P&P Committee - (Committee) -> 03 MS-Surgery Department - (Committee) -> 04 MS-

Performance Improvement/Pharmacy & Therapeutics Committee - (Committee) -> 05 MS-Medical Executive - (Committee) -

> 07 BOD-Quality (P&P Review) - (Committee) -> 09 BOD-Board of Directors - (Committee)

Monitoring Medication Storage TemperaturePending Approval8/17/20230

Medication Management Policies (MM)

Summary Of Changes: Reviewed with no changes; updated date accessed for reference

Moderators: Newman, Cindi (cnewman)
Lead Authors: Kutza, Chris (ckutza)

Approvers: 01 P&P Committee -> 04 MS-Performance Improvement/Pharmacy & Therapeutics Committee - (Committee) -> 05 MS-

Medical Executive - (Committee) -> 07 BOD-Quality (P&P Review) - (Committee) -> 09 BOD-Board of Directors - (Committee)

NEW:: Transfusion Transmitted Infectious Disease Notification Pending Approval 8/17/2023 0

Laboratory Services Policies (LB)

Summary Of Changes: New to the portal. Policy was found in the department policies and is required for survey and CLIA. Approved by Medical

Director in 2020. New: Clarification needed by Board Quality, changed verbiage from virus or parasite to infectious agent and added transfusion transmissible disease marker as well as disposition process of quarantined blood. Did not list all

infectious diseases instead included most common.

Moderators: Newman, Cindi (cnewman)

Lead Authors: Kuwahara, Dawn (dkuwahara), Ramos, Karen (kramos)

ExpertReviewers: Medical Director-Lab

Approvers: Kuwahara, Dawn (dkuwahara) -> 01 P&P Committee - (Committee) -> 02 MS-Medicine Department - (Committee) -> 03 MS-Medicine Department - (Committee) - (Committee)

Surgery Department - (Committee) -> 04 MS-Performance Improvement/Pharmacy & Therapeutics Committee -

Page 3 of 5 HospitalPORTAL

Run by: Newman, Cindi (cnewman) Run date: 08/17/2023 7:32 PM

Listing of currently pending and/or upcoming document tasks grouped by committee.

(Committee) -> 05 MS-Medical Executive - (Committee) -> 07 BOD-Quality (P&P Review) - (Committee) -> 09 BOD-Board of Directors - (Committee)

Pharmacy and Therapeutics Committee

Pending Approval

8/17/2023

0

Medication Management Policies (MM)

Summary Of Changes: Claified language regarding conflict of interest to separate attachment from body of policy

Moderators: Newman, Cindi (cnewman)
Lead Authors: Kutza, Chris (ckutza)

Approvers: 01 P&P Committee -> 04 MS-Performance Improvement/Pharmacy & Therapeutics Committee - (Committee) -> 05 MS-

Medical Executive - (Committee) -> 07 BOD-Quality (P&P Review) - (Committee) -> 09 BOD-Board of Directors - (Committee)

Placenta Disposition Pending Approval 8/17/2023 0

Laboratory Services Policies (LB)

Summary Of Changes: Removed Birthplace and added ER.

>>>>> Permission for Disposal and Release of Specimens:

• No tissue may be released to a patient for disposal. (California Health and Safety Code 25157.3 and 25157.5). This is because of hazard of infections or potentially infectious material. If a patient requests to retain the placenta, pathology

will only release to a mortuary of their choosing.

Moderators: Newman, Cindi (cnewman)

Lead Authors: Kuwahara, Dawn (dkuwahara), Ramos, Karen (kramos)

ExpertReviewers: Medical Director-Lab

Approvers: Kuwahara, Dawn (dkuwahara) -> 01 P&P Committee - (Committee) -> 02 MS-Medicine Department - (Committee) -> 03 MS-

Surgery Department - (Committee) -> 04 MS-Performance Improvement/Pharmacy & Therapeutics Committee - (Committee) -> 05 MS-Medical Executive - (Committee) -> 07 BOD-Quality (P&P Review) - (Committee) -> 09 BOD-Board of

Directors - (Committee)

Remote Pharmacist Services Pending Approval 8/17/2023 0

Medication Management Policies (MM)

Summary Of Changes: Reviewed, no changes

Moderators: Newman, Cindi (cnewman)
Lead Authors: Kutza, Chris (ckutza)

indications.

Approvers: 01 P&P Committee -> 04 MS-Performance Improvement/Pharmacy & Therapeutics Committee - (Committee) -> 05 MS-

Medical Executive - (Committee) -> 07 BOD-Quality (P&P Review) - (Committee) -> 09 BOD-Board of Directors - (Committee)

Sterile Compounding Procedures 8390-03 Pending Approval 8/17/2023 0

Pharmacy Dept

Summary Of Changes: **Reviewed, no changes**

Moderators: Newman, Cindi (cnewman)
Lead Authors: Kutza, Chris (ckutza)

Approvers: 01 P&P Committee -> 04 MS-Performance Improvement/Pharmacy & Therapeutics Committee -- (Committee) -> 05 MS-

Medical Executive - (Committee) -> 07 BOD-Quality (P&P Review) - (Committee) -> 09 BOD-Board of Directors - (Committee)

Surge Planning-Pharmacy Pending Approval 8/17/2023 0

Emergency Preparedness Policies (EP)

Summary Of Changes: Made formatting changes; updated list of 503b suppliers to what we are currently using.

Moderators: Newman, Cindi (cnewman)

Lead Authors: Kutza, Chris (ckutza), Winkler, Jessica (jwinkler), MANAGER, ED (edmanager)

Page 4 of 5 HospitalPORTAL

Sonoma Valley Hospital

Run by: Newman, Cindi (cnewman) Run date: 08/17/2023 7:32 PM

Listing of currently pending and/or upcoming document tasks grouped by committee.

Approvers: 00 Clinical P&P multidisciplinary review -> 01 P&P Committee - (Committee) -> 04 MS-Performance Improvement/Pharmacy

& Therapeutics Committee - (Committee) -> 05 MS-Medical Executive - (Committee) -> 07 BOD-Quality (P&P Review) -

(Committee) -> 09 BOD-Board of Directors - (Committee)

Vaccine Screening-Pneumococcal and Influenza

Pending Approval

8/17/2023

8/17/2023

0

0

Medication Management Policies (MM)

Summary Of Changes: Reviewed, no changes. Please note that the title in the portal is "Vaccine Screening-Pneumococcal and Influenza" whereas

the title of the acutal policy is "Influenza Vaccine Screening"

Moderators: Newman, Cindi (cnewman)
Lead Authors: Kutza, Chris (ckutza)
ExpertReviewers: Taylor, Jane (jtaylor)

Approvers: 01 P&P Committee -> 04 MS-Performance Improvement/Pharmacy & Therapeutics Committee - (Committee) -> 05 MS-

Medical Executive - (Committee) -> 07 BOD-Quality (P&P Review) - (Committee) -> 09 BOD-Board of Directors - (Committee)

Vancomycin Protocol Pending Approval 8/17/2023 0

Medication Management Policies (MM)

Summary Of Changes: Reviewed, no changes

Moderators: Newman, Cindi (cnewman)
Lead Authors: Kutza, Chris (ckutza)

Approvers: 01 P&P Committee -> 04 MS-Performance Improvement/Pharmacy & Therapeutics Committee - (Committee) -> 05 MS-

Medical Executive - (Committee) -> 07 BOD-Quality (P&P Review) - (Committee) -> 09 BOD-Board of Directors - (Committee)

Pending Approval

Warming Fluids for IV and Irrigation Purposes, Storage and Handling

Medication Management Policies (MM)

Summary Of Changes: Reviewed, no changes. Deleted attachment embedded in policy and uploaded appropriate documents to portal

Moderators: Newman, Cindi (cnewman)
Lead Authors: Kutza, Chris (ckutza)
ExpertReviewers: Cornell, Kelli (kcornell)

Approvers: 01 P&P Committee -> 04 MS-Performance Improvement/Pharmacy & Therapeutics Committee - (Committee) -> 05 MS-

Medical Executive - (Committee) -> 07 BOD-Quality (P&P Review) - (Committee) -> 09 BOD-Board of Directors - (Committee)

Page 5 of 5 HospitalPORTAL



Page 1 of 5

Transfusion Transmitted Infectious Disease Notification

DEPARTMENT: Organizational EFFECTIVE: 03/2020

REVISED: <u>02/2023</u>:

NEW POLICY

policy was filed under the Laboratory's department policies and is not in the policy portal. It should be an organizational policy.

WHY:

Policy is required for accreditation and CLIA

OWNER:

Chief Ancillary Officer

AUTHORS/REVIEWERS:

Laboratory Manager Laboratory Medical Director



Transfusion Transmitted Infectious Disease Notification

Page 2 of 5

DEPARTMENT: Organizational EFFECTIVE: 03/2020

REVISED: 02/2023:

PURPOSE:

This policy describes the process for investigating transfusion transmitted infectious disease when information is received after the time of donation that may affect the safety to any donor blood or recipient. Transmission-transmitted infections are predominantly acquired by the transfusion of a virus or parasite of an infectious agent, in which a delay generally occurs between transfusion and manifestation of symptoms and signs of infection.

POLICY:

All transfusion transmitted infectious disease <u>agents</u> will be investigated and notification is made to recipients who may have been exposed to a transfusion transmissible disease <u>agent</u> from a blood transfusion.

PROCEDURE:

Blood Productions may be quarantined, returned, or destroyed upon notification by the blood supplier for a variety of reasons. A biological recall indicates the product was incorrectly collected or processed. A market withdrawal is associated with a product that has been delivered to the consignee but now additional information on the donor makes the product unsuitable for transfusion. A traceback is initiated when the supplier finds a donor to have a transfusion transmissible disease <u>agent</u> and contacts the consignees to determine the disposition of past donations from this donor, possibly going back years. Once the process is initiated the response is similar in all cases.

Traceback/Lookback involves:

- Tracking and identification of the location and disposition of blood component products that were manufactured from donations by a particular donor.
- The steps taken to track and quarantine unsuitable blood or blood components.
- The notification of consignees when a previous donor subsequently tests positive for the an most infectious disease markers.

Recipient Traceback Notifications

Investigation is conducted to notify recipients who may have been exposed to a transfusion transmissible disease <u>marker</u> from a blood transfusion. Most commonly, confirmatory test is positive for one of the following:



Transfusion Transmitted Infectious Disease Notification

Page 3 of 5

DEPARTMENT: Organizational EFFECTIVE: 03/2020

REVISED: 02/2023:

1. Anti-Human Immunodeficiency Virus (HIV)-1

- 2. Anti-HIV 2
- 3. HIV Nucleic Testing (NAT)
- 4. Anti-Hepatitis C Virus (HCV)
- 5. HCV NAT

HIV TRACEBACK ("LOOKBACK")

When the supplemental (additional, more specific) test for HIV is positive or when the screening test is reactive and there is no available supplemental test that is approved for such use by FDA, the blood bank must notify transfusion recipients of previous collections of blood and blood components at increased risk of transmitting HIV infection, or the recipient's physician of record, of the need for recipient HIV testing and counseling. The blood bank must also notify the recipient's physician of record, or a legal representative or relative if the recipient is a minor, deceased, judged incompetent by a State Court, or if the recipient is competent but State Law permits a legal representative or relative to receive information on behalf of the recipient. Reasonable attempts must be made to perform the notification within 12 weeks after receiving the supplemental test evidence of HIV infection from VITALANT BLOOD SERVICES. (Blood Bank Service).

HCV Traceback ("Lookback")

Requirements are similar for notification for HCV with the exception that notification is not required for patients who are deceased.

- A. Recipient Traceback ("Lookback") Notification is received from VITALANT BLOOD SERVICES when:
 - Subsequent to market withdrawal for one of the markers specified above now with a confirmatory test of positive.
 - Donor of a distributed product has an infection requiring traceback.
- B. The Blood Bank Clinical Lab Scientist assigned at the time will look up the following and log in Transfusion Transmitted Infectious Disease Investigation Log:
 - Date
 - Donor Identification Number and Component
 - Patient Name
 - Patient Medical Record Number
 - Physician taking care of the patient
- C. Quarantine in date blood and blood components as directed on bottom shelf in refrigerator if available. The Blood Bank Service will notify the Lab regarding the disposition of the quarantined blood whether it be destroyed or returned.



Transfusion Transmitted Infectious Disease Notification

Page 4 of 5

DEPARTMENT: Organizational EFFECTIVE: 03/2020

REVISED: 02/2023:

D. If confirmatory results are pending, the letter is filed under pending confirmation. If all testing is complete, go to step F.

- E. If test is negative, no further action is required. If test is positive, continue to step F.
- F. File screen and confirmation together under "Confirmed"
- G. Send HIV/HCV Lookback Notification Form to the physician. Reasonable attempts will be made to contact the recipient with 12 weeks. Document date/time for all attempts made to contact appropriate party.
- H. When form is returned, note date responded on log.
- I. Make a copy for our records and send original Lookback Notification form to Medical Records for patient's chart.
- J. File form in "Returned Forms" area of binder.
- K. Complete Traceback Recipient Status form with as much information as possible. This form needs to be returned within 60 days. Make a copy for our files, send original to Donor and Client Support Center. If VITALANT BLOOD SERVICES does not received the form back within 60 days, they will send a second (and FINAL) notice for which a response is required in 30 days.

NOTE:

In the event the provider refuses or otherwise fails to notify recipient or is no longer at the facility, the lab will notify the patient. For non-HIV and non-HCV notification letters from VITALANT BLOOD SERVICES, refer the letter to the pathologist who will determine if notification is necessary.

REFERENCES:

Standards for Blood Banks and Transfusion Services 33rd Edition. April 2022 Code of Federal Regulations (CFR) Requirements for HIV/HCV Lookback Requirements

OWNER:

Chief Ancillary Officer

AUTHORS/REVIEWERS:

Laboratory Manager Board Quality Committee



Page 5 of 5

Transfusion Transmitted Infectious Disease Notification

DEPARTMENT: Organizational EFFECTIVE: 03/2020

REVISED: <u>02/2023</u>:

APPROVALS:

Policy & Procedure Team:
Medicine Committee:
Surgery Committee:
Performance Improvement/
Pharmacy & Therapeutics Committee
Medical Executive Committee:
The Board of Directors:

